Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04611568
Other study ID # STUDY00019372
Secondary ID NCI-2020-01301ST
Status Recruiting
Phase N/A
First received
Last updated
Start date May 14, 2019
Est. completion date December 30, 2024

Study information

Verified date March 2024
Source OHSU Knight Cancer Institute
Contact Elizabeth Stoos
Phone 503-418-9356
Email stoos@ohsu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies how well a health educational campaign works in increasing early detection of melanoma in Oregon. The health educational campaign may provide information to help people learn about the early signs of melanoma. Increased education in Oregon may decrease the number of people who die from melanoma and increase the number of melanomas that are identified at an earlier stage.


Description:

PRIMARY OBJECTIVES: I. To measure the change in melanoma literacy in Oregon, Washington, and Utah over five years (relative to baseline) and determine if there is a statistically significant difference in literacy in Oregon (where the educational campaign occurred) as compared to the non-participating states (Washington and Utah). II. To determine if there is an association between melanoma literacy and 1) stage at diagnosis, 2) tumor depth, 3) incidence, and 4) mortality rates in Oregon, Washington, and Utah. III. To determine if the cost of care for melanoma in Oregon is impacted by melanoma literacy and/or tumor stage. OUTLINE: MEDIA CAMPAIGN: Participants view digital media strategies. PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum. MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material. HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture.


Recruitment information / eligibility

Status Recruiting
Enrollment 75000
Est. completion date December 30, 2024
Est. primary completion date December 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Individuals, melanoma patients, skin service providers and health care providers interested in awareness and educational campaign Exclusion Criteria: - No one will be intentionally excluded

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Educational Intervention
Receive educational and training material
Educational Intervention
Receive educational lecture
Behavioral:
Health Education
Receive melanoma curriculum
Media Campaign
View digital media strategies
Other:
Survey Administration
Complete survey

Locations

Country Name City State
United States OHSU Knight Cancer Institute Portland Oregon

Sponsors (3)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute Melanoma Research Foundation, Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Statewide awareness (level of knowledge and detection) Will compare the level of knowledge and early detection of melanoma between participants in Oregon who received the educational campaign and those who did not in Washington and Utah. Up to completion of surveys, assessed up to 5 years
Primary Cancer data collection (correlation with demographic and geographic factors) Will collect baseline and post-intervention data from Oregon State Cancer Registry (OSCaR) on melanoma diagnoses to correlate the incidence and pathologic factors with demographic and geographic factors. Up to 5 years
Primary Cost data Will compare reports of cost data between those who received the health education campaign and those who did not. Up to 5 years
Primary Reach of educational campaign Will determine the reach of the educational campaign across Oregon using volunteer activity logs, volunteer training logs, and website usage analysis. Up to completion of surveys, assessed up to 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study